Clarivate

Clarivate

CLVT
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Market Cap: $1.7BFounded: 2016Employees: 10,000+HQ: London, United Kingdom

Overview

Clarivate Plc is a mission-driven company that fuels global breakthroughs by connecting organizations to trusted, transformative intelligence. It has established itself as an indispensable partner through strategic acquisitions, integrating premier brands like Web of Science, Cortellis, and Derwent into a comprehensive data and analytics ecosystem. The company's strategy leverages a 'human-in-the-loop' AI approach to deliver predictive insights and workflow tools that de-risk R&D, accelerate time-to-market, and protect intellectual property for thousands of clients worldwide.

AI / Machine LearningDigital Health

Technology Platform

An interconnected AI-powered platform built on massive proprietary datasets (scientific literature, patents, drug pipelines, real-world evidence) and enhanced by a 'human-in-the-loop' methodology where PhD-level experts validate and enrich AI outputs.

Funding History

1
IPOUndisclosed

Opportunities

Clarivate is poised to capitalize on the massive, growing demand for data-driven decision tools in life sciences R&D, academic research, and IP management.
The integration of generative AI and predictive analytics into its trusted data ecosystem presents a significant greenfield opportunity to deliver higher-value insights and deepen client engagement.

Risk Factors

Major risks include execution challenges in integrating large acquisitions, competitive disruption from both established rivals and AI-native startups, and potential regulatory changes affecting data access and privacy.
Macroeconomic sensitivity affecting client R&D and library budgets is also a concern.

Competitive Landscape

Clarivate competes with specialized giants across its segments: Elsevier (Academia, Life Sciences), IQVIA (Life Sciences RWE), and Anaqua/LexisNexis (IP). Its key advantage is the unique combination of authoritative, interlinked data assets across the innovation lifecycle (research, patents, drug development) enhanced by deep subject-matter expertise.